Influence of acute treatment with Sibutramine (cas 106650-56-0) on the sympathetic neurotransmission of the young rat vas deferens

Add time:08/07/2019    Source:sciencedirect.com

The effects of acute treatment with Sibutramine (cas 106650-56-0) on the peripheral sympathetic neurotransmission in vas deferens of young rats were still not evaluated. Therefore, we carried out this study in order to verify the effects of acute sibutramine treatment on the neuronal- and exogenous agonist-induced contractions of the young rat vas deferens. Young 45-day-old male Wistar rats were pretreated with sibutramine 6 mg/kg and after 4 h the vas deferens was used for experiment. The acute treatment with sibutramine was able to increase the potency (pD2) of noradrenaline and phenylephrine. Moreover, the efficacy (Emax) of noradrenaline was increased while the efficacy of serotonin and nicotine were decreased. The maximum effect induced by a single concentration of tyramine was diminished in the vas deferens from treated group. Moreover, the leftward shift of the noradrenaline curves promoted by uptake blockers (cocaine and corticosterone) and β-adrenoceptor antagonist (propranolol) was reduced in the vas deferens of treated group. The initial phasic and secondary tonic components of the neuronal-evoked contractions of vas deferens from treated group at the frequencies of 2 Hz were decreased. Moreover, only the initial phasic component at 5 Hz was diminished by the acute treatment with sibutramine. In conclusion, we showed that the acute treatment with sibutramine in young rats was able to affect the peripheral sympathetic nervous system by inhibition of noradrenaline uptake and reduction of the neuronal content of this neurotransmitter, leading to an enhancement of vas deferens sensitivity to noradrenaline.

We also recommend Trading Suppliers and Manufacturers of Sibutramine (cas 106650-56-0). Pls Click Website Link as below: cas 106650-56-0 suppliers

Prev:Detection of Sibutramine (cas 106650-56-0) in adulterated dietary supplements using attenuated total reflectance-infrared spectroscopy
Next:Characterization, stability, and pharmacokinetics of Sibutramine (cas 106650-56-0)/β-cyclodextrin inclusion complex)